New Outcomes and Cost Data Further Supports St. Jude Medical Leadership in Quadripolar Technology at HRS 2015
May 14 2015 - 2:57PM
Business Wire
Use of SJM Quartet™ LV lead showed:
- Reduced mortality of 24% with a high
percent of bi-v pacing compared to bipolar leads
- Reduced risk of shock by 13% compared
to bipolar leads
- Reduced post-implant HF hospitalization
of 31% and 39% reduction in associated costs compared to bipolar
leads
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced the presentation of important data around
its SJM™ Quadra CRT System during the Heart Rhythm Society's (HRS)
36th annual scientific sessions.
Multiple presentations showcase improved clinical outcomes,
increased survival and better cost utilization with the St. Jude
Medical quadripolar cardiac resynchronization therapy (CRT) system.
Combined with a strong product pipeline, the growing body of
clinical evidence supporting the SJM Quadra CRT System now includes
more than 130 publications, further substantiating the company’s
unique and comprehensive portfolio of heart failure management
solutions.
A data presentation titled Incremental Survival Benefit of High
Percent Biventricular Pacing in Quadripolar CRT was presented by
Dr. Michael R. Gold, who led the study. The analysis looked at
8,973 patients with high and low percentages of biventricular
(bi-v) pacing with the SJM Quadra CRT System, including the
Quartet™ LV Lead, compared to a standard bipolar pacing lead. High
bi-v pacing was defined as resynchronization pacing rates equal to
or greater than 93 percent. The mortality benefit of quadripolar
leads was observed in both the high and low percentages of bi-v
pacing patient groups. In patients with a high percentage of bi-v
pacing, the risk of mortality was 24 percent lower in those with a
Quartet LV lead than those with a conventional bipolar lead.
“These data show how our continued innovation demonstrates
improved clinical and economic outcomes in cardiac
resynchronization therapy,” said Dr. Mark D. Carlson, chief medical
officer for St. Jude Medical. “The SJM Quadra CRT Systems are a key
component of our leadership in heart failure solutions.”
Data was presented by Dr. Mintu P. Turakhia during a session
titled Quadripolar LV leads are Associated with Decreased Shock
Burden in CRT-D Patients. The analysis evaluated nearly 11,000
patients implanted with a CRT-D (8,640 with a quadripolar lead vs.
2,303 with a bipolar lead) found that the shock-free survival
(chance of not getting an initial shock) was higher in patients
implanted with the Quartet LV lead, showing a reduced risk of
shocks by 13 percent compared to bipolar LV leads.
Additional data presentations for the St. Jude Medical
quadripolar pacing system included Decreased Heart Failure Event
Rates and associated Costs with Quadripolar versus Bipolar CRT-D
systems, presented by Dr. Raffaele Corbisiero. These data showed
that the Quartet LV lead exhibited a 31 percent reduction in
post-implant heart failure hospitalization rates in the U.S. and a
significant 39.8 percent reduction in associated costs compared to
CRT-D patients with bipolar LV leads.
Quadripolar Pacing Technology from St. Jude
Medical
St. Jude Medical introduced the industry’s first
quadripolar CRT pacing system with the Quartet LV lead, featuring
four uniquely spaced electrodes. The quadripolar CRT pacing system
offers physicians the ability to effectively and efficiently manage
the ever-changing needs of patients with heart failure. The system
integrates multiple pacing configurations that enable physicians to
optimize the system at implant and follow-up, as well as better
manage common pacing complications without having to surgically
reposition the lead.
St. Jude Medical’s Quartet lead design allows the physician to
implant the lead in the most stable position without making
trade-offs in electrical performance. This includes pacing closer
to the base of the left ventricle, which studies associate with
better patient outcomes and which may be more difficult with
traditional bipolar leads. The quadripolar pacing electrodes also
provide physicians more options to optimize CRT performance, such
as pacing around scar tissue in the heart and avoiding the most
common pacing complications.
About St. Jude Medical’s Heart Failure Business
Approximately 26 million people worldwide suffer from heart
failure. St. Jude Medical collaborates with heart failure
specialists, clinicians and advocacy partners to provide
innovative, cost-effective solutions for heart failure patients
around the world. For more information about St. Jude Medical’s
focus on heart failure, visit the St. Jude Medical Heart Failure
Media Kit.
About St. Jude Medical
St. Jude Medical is a global medical device manufacturer
dedicated to transforming the treatment of some of the world’s most
expensive epidemic diseases. The company does this by developing
cost-effective medical technologies that save and improve lives of
patients around the world. Headquartered in St. Paul, Minn., St.
Jude Medical has four major clinical focus areas that include
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com or
follow us on Twitter @SJM_Media.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Annual Report on Form 10-K for the fiscal year ended
January 3, 2015. The Company does not intend to update these
statements and undertakes no duty to any person to provide any such
update under any circumstance.
St. Jude Medical, Inc.Investor Relations:J.C. Weigelt,
651-756-4347jweigelt@sjm.comorMedia Relations:Kate Stoltenberg,
651-756-3388kstoltenberg@sjm.com
SJM (NYSE:STJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Apr 2023 to Apr 2024